Nonalcoholic steatohepatitis

Indian Journal of Gastroenterology

Volumn 20, Issue SUPPL. 1, 2001, Pages

  Sanyal, A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; LIPID; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ALGORITHM; CHRONIC LIVER DISEASE; CLINICAL PROTOCOL; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; FATTY LIVER; HEPATITIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS;

CHRONIC DISEASE; FATTY LIVER; HEPATITIS; HUMANS; INSULIN RESISTANCE; OXIDATIVE STRESS;

EID: 0035084099     PISSN: 02548860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (79)

1. Nonalcoholic steatohepatitis
2. Nonalcoholic steatohepatitis
3. Nonalcoholic steatohepatitis: Tightening the morphological screws on a hepatic rambler
4. Liver disturbances in obesity and diabetes mellitus
5. Nonalcoholic steatohepatitis: An expanded clinical entity
6. Fatty liver hepatitis and cirrhosis in obese patients
7. Hepatobiliary effects of obesity and weight-reducing surgery
8. Liver transplantation for jejunoileal bypass-associated cirrhosis
9. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
10. Nonalcoholic steatohepatitis: A study of 49 patients
11. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
12. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
13. Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis
14. Association of nonalcoholic fatty liver disease with insulin resistance
15. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?
16. Non-alcoholic fatty liver: Another feature of the metabolic syndrome?
17. Liver pathology and the metabolic syndrome X in severe obesity
18. Steatohepatitis associated with limb lipodystrophy
19. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerothic cardiovascular disease
20. Correlations between fatty acid and glucose metabolism. Potential explanation of insulin resistance of puberty
21. Lipid-carbohydrate interactions in post-absorptive non-insulin-dependent diabetic patients
22. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects
23. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
24. Effects of free fatty acids on glucose production and utilization in man
25. Formation and degradation of glycogen
26. Glucose metabolism in the liver: Glycolysis and gluconeogenesis
27. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: A precursor defect for dyslipidemia?
28. The glucose-fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus
29. Glucose and insulin metabolism in cirrhosis
30. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis
31. Hepatic cytochrome P450 2El is increased in patients with nonalcoholic steatohepatitis
32. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
33. Metformin reverses fatty liver disease in obese, leptin-deficient mice
34. Synthesis of eicosanoids by circulating mononuclears in healthy people and in patients with liver cirrhosis
35. Adaptive responses to fatty acids are mediated by the regulated expression of cytochromes P450
36. Phospholipase-induced modulation of rat liver mixed-function oxidase activity
37. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity
38. Fatty acid regulation of gene expression. Its role in fuel partitioning and insulin resistance
39. Fettstoffwechsel und insulinresistenz - Klinik und pathobiochemie
40. Fuel selection in human skeletal muscle in insulin resistance: A reexamination
41. Mitochondrial abnormalities in non-alcoholic steatohepatitis
42. Hepatotoxicity due to mitochondrial dysfunction
43. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus
44. The measurement of alcohol consumption and alcohol-related problems
45. Tools of alcohol detection
46. Use of enzymes for the diagnosis of alcohol-related organ damage
47. Serum mitochondrial aspartate aminotransferase: A sensitive marker of alcoholism with or without alcoholic hepatitis
48. Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: Diagnostic value and interpretation in a liver unit
49. Desialyted transferrin as a serologic marker of chronic excessive alcohol ingestion
50. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: An aid to diagnosis
51. Serum cholinesterase in patients with fatty liver
52. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease
53. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty
54. Diffuse liver disease
55. Ultrasonographical diagnosis of fatty liver: Significance of the liver-kidney contrast
56. Obesity and liver disease: Evaluation of fatty infiltration of the liver using ultrasonic attenuation
57. Diagnosis of fatty liver with MR imaging
58. The radiographic signs of fatty liver
59. Computed tomography attenuation values in fatty liver
60. Difference between liver and spleen CT numbers in the normal adult: Its usefulness in predicting the presence of diffuse liver disease
61. The relation of liver fat to computed tomography numbers: A preliminary experimental study in rabbits
62. Natural history of alcoholic hepatitis: III. Histologic changes
63. Detection of lipid in abdominal tissues with opposed-phase gradient echo images at 1.5 T: Techniques and diagnostic importance
64. Proton MR spectroscopy in quantitative in vivo determination of fat content in human steatosis
65. Introduction of fast MR imaging in the assessment of hepatic steatosis
66. Generation of ATP from fatty acids and ketone bodies
67. Dual-energy CT in the diagnosis and quantification of fatty liver: Limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload
68. Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet
69. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?
70. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol induced steatohepatitis: A pilot study
71. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
72. Body composition and hepatic steatosis as precursors for fibrotic liver disease
73. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
74. Nonalcoholic steatohepatitis in obesity: A reversible condition
75. Effect of moderate exercise on insulin sensitivity and substrate metabolism during post-exercise recovery in cirrhosis
76. Medical significance of peroxisome proliferator activated receptors
77. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer
78. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatoheparitis
79. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot